UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
AMENDMENT NO. 1
TO
SCHEDULE 13D
Under the Securities Exchange Act Of 1934
BMJ Medical Management, Inc.
(Name of Issuer)
Common Stock, $0.001 par value per share
(Title of Class of Securities)
055950 10 9
(CUSIP Number)
M. Steven Alexander with copies to:
Paribas John M. Reiss, Esq.
787 Seventh Avenue White & Case LLP
New York, NY 10019 1155 Avenue of the Americas
212-841-2000 New York, NY 10036
212-819-8200
(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)
November 10, 1998
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box ( ).
<PAGE>
- --------------------------------------------------------------------------------
CUSIP NO. 055950 10 9 Page 3 of 8 Pages
- --------------------------------------------------------------------------------
- -------- -----------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Paribas I.R.S. Identification No. 132937443
- -------- -----------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)( )
(b)(X)
- -------- -----------------------------------------------------------------------
3 SEC USE ONLY
- -------- -----------------------------------------------------------------------
4 SOURCE OF FUNDS
WC
- -------- -----------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED ( )
PURSUANT TO ITEMS 2(d) or 2(e)
- -------- -----------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Republic of France
- -------------------------------- ---- ------------------------------------------
NUMBER OF SHARES BENEFICIALLY 7 SOLE VOTING POWER
OWNED BY EACH REPORTING PERSON 340,000<F1>(see discussion in Items 4 & 5)
WITH
---- ------------------------------------------
8 SHARED VOTING POWER
0
---- ------------------------------------------
9 SOLE DISPOSITIVE POWER
340,000<F1>(see discussion in Items 4 & 5)
---- ------------------------------------------
10 SHARED DISPOSITIVE POWER
0
- -------- -----------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
340,000<F1>(see discussion in Items 4 & 5)
- -------- -----------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES ( )
------- -----------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
1.6% (see discussion in Items 4 & 5)
- -------- -----------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
BK
- -------- -----------------------------------------------------------------------
<F1> Paribas may be deemed to be the beneficial owner of the common stock of BMJ
Medical Management, Inc. reported herein through its ownership of Paribas
Principal Inc. Such shares of BMJ Medical Management, Inc. are not included
above so as to avoid double counting.
<PAGE>
Page 4 of 8 Pages
- -------- -----------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Paribas Principal Incorporated I.R.S. Identification No. 133529118
- -------- -----------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ( )
(b) (X)
- -------- -----------------------------------------------------------------------
3 SEC USE ONLY
- -------- -----------------------------------------------------------------------
4 SOURCE OF FUNDS
WC
- -------- -----------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(d) or 2(e) ( )
- -------- -----------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
State of New York
- -------------------------------- ---- ------------------------------------------
NUMBER OF SHARES BENEFICIALLY 7 SOLE VOTING POWER
OWNED BY EACH REPORTING PERSON 2,539,173 (see discussion in Items 4 & 5)
WITH
---- ------------------------------------------
8 SHARED VOTING POWER
0
---- ------------------------------------------
9 SOLE DISPOSITIVE POWER
2,539,173 (see discussion In Items 4 & 5)
---- ------------------------------------------
10 SHARED DISPOSITIVE POWER
0
- -------- -----------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,539,173
(see discussion in Items 4 & 5)
- -------- -----------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES ( )
- -------- -----------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
11.86%
- -------- -----------------------------------------------------------------------
14 TYPE OF REPORTING PERSON
CO
- -------- -----------------------------------------------------------------------
<PAGE>
Page 5 of 8 Pages
Amendment No. 1 to Schedule 13D
This Amendment No. 1 amends and supplements the Schedule 13D relating
to the common stock, $0.001 par value per share ("Common Stock") of BMJ Medical
Management, Inc., a Delaware Corporation ("the Company"), the principal
executive offices of which are located at 4800 North Federal Highway, Suite
101-E, Boca Raton, Florida 33431.
Item 3. Source and Amount of Funds or Other Consideration.
Item 3 is hereby amended to add at the end thereof the following:
"On November 9, 1998, PPI purchased and the Company issued without
additional consideration, 959,038 warrants (the "Performance Warrants")
pursuant to the Securities Purchase Agreement.
Item 4. Purpose of the Transaction
The first parenthetical appearing in the first paragraph of Item 4 is
amended and restated in its entirety as follows:
"(or the right to purchase shares pursuant to the Preferred Stock, the
Initial Warrants and the Performance Warrants)".
The second paragraph of Item 4 is amended and restated in its entirety as
follows:
In addition to the Preferred Stock, the Initial Warrants and the
Performance Warrants, pursuant to the Securities Purchase Agreement, PPI
may, subject to the provisions of the Securities Purchase Agreement and the
Certificate of Designation for the Preferred Stock, acquire (i) $3,000,000
of shares of a new series of convertible preferred stock (the "Additional
Preferred Stock") convertible into shares of Common Stock on or before
September 8, 1998, (ii) certain additional common stock purchase warrants
(the "Additional Warrants") on or before September 8, 1998 and (iii)
certain common stock purchase warrants (the "Registration Warrants") for
failure of the Company to effect certain registration rights. The amount of
all such securities which may be purchased or received is dependent upon
various factors and cannot be determined at this time. Pursuant to the
Certificate of Designation for the Preferred Stock, PPI may acquire certain
common stock purchase warrants (the "Redemption Warrants" and together with
the Additional Warrants, the Performance Warrants and Registration
Warrants, the "PPI Warrants" and collectively with the Paribas Warrants,
the "Warrants") for failure of the Company to affect a redemption of the
Preferred Stock under certain circumstances.
Item 5. Interest in Securities of the Issuer
The first two paragraphs of Item 5(a) are amended and restated in its
entirety to read as follows:
<PAGE>
Page 6 of 8 Pages
"As of the date of this statement, Paribas' beneficial ownership of
340,000 shares of Common Stock constitutes beneficial ownership of 1.6% of
the total number of outstanding Common Stock (all of which Paribas has the
right to acquire pursuant to the Paribas Warrants issued to it).
PPI's beneficial ownership of 2,539,173 shares of Common Stock
(all of which PPI has the right to acquire either pursuant to the
Initial Warrants, Performance Warrants or conversion of the Preferred
Stock) constitutes beneficial ownership of 11.86% of the total number
of shares, of outstanding Common Stock. Paribas may be deemed to be
the beneficial owner of the shares of Common Stock beneficially owned
by PPI."
The last sentence of the Section titled "Securities Purchase Agreement" of
Item 6 is amended and restated in its entirety to read as follows:
"PPI is entitled to certain common stock purchase warrants if the
Company fails to cause a shelf registration to become effective within 90
days of the date of a notice delivered by PPI to effect such registration
in accordance with the Securities Purchase Agreement."
<PAGE>
Page 7 of 8 Pages
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Dated: November 12, 1998
PARIBAS
By: /s/ M.S. Alexander
------------------------------------
Name: M.S. Alexander
Title: Managing Director
<PAGE>
Page 8 of 8 Pages
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Dated: November 12, 1998
PARIBAS PRINCIPAL INCORPORATED
By: /s/ M.S. Alexander
------------------------------------
Name: M.S. Alexander
Title: President
